Anti-Vaping Scientists Have an Integrity Problem

Flawed Methods, Faked Images, and the War on Harm Reduction

The anti-vaping crusade was dealt another serious blow following the retraction of a study in May claiming nicotine “plays a critical role” in the progression of breast cancer. The research could have been significant because it challenged the longstanding conclusion that nicotine is a generally low-risk stimulant. But Nature Communications finally pulled the paper, originally published in January 2021, after “concerns were raised regarding highly similar images”—a diplomatic way of saying the authors fabricated data underlying their results.

Yale psychiatrist Sally Satel put it more bluntly: “Yet another alarmist study re nicotine (read: vaping, pouches, etc.) that is based on bad methodology . . . in this case, worse: FAKE data.” Satel’s reference to “yet another study” highlights the broader issue of lousy science in anti-vaping research, where biased assumptions, poor experimental design–and sometimes outright fraud–undermine integrity and mislead the public.

 

Nicotine and breast cancer  

 

The study examined nicotine’s effect on breast cancer metastasis. However, post-publication scrutiny revealed significant errors. There were critical issues with the experimental design, including assumptions that failed to mimic real-world vaping conditions. Specifically, the study unrealistically exposed cell cultures and sick mice to nicotine, a design that has little to do with how generally healthy adults are exposed through vapor inhalation, rendering the findings largely irrelevant to human health. 

 

The much larger problem was that the study’s data was fake; multiple images included in the paper appear to be duplicates with slight modifications. Whatever conclusions could have been drawn from these dubious experiments were totally invalidated by the manipulated images. 

 

A troubling pattern

 

This retraction is not an isolated incident but part of a troubling pattern in anti-vaping research. Many studies in this field suffer from confirmation bias, where researchers appear to design experiments to produce negative outcomes that align with preconceived anti-vaping narratives. For instance, the retracted study ignored the comparative harm reduction of vaping versus combustible tobacco, a well-documented public health benefit supported by organizations like Public Health England, which estimates vaping to be 95% less harmful than smoking. 

 

Instead, the retracted paper focused on worst-case scenarios, neglecting dose-response relationships critical to toxicological research. Such selective framing fuels public misconceptions and supports restrictive policies that drive adult former smokers back to deadly cigarettes.

 

The rush to publish anti-vaping studies often bypasses rigorous peer review, as seen in this case. The initial acceptance of the study by Nature Communications, a prestigious journal, suggests a lapse in editorial oversight, possibly driven by the topical allure of vaping-related health scares. Indeed, the only other study to implicate nicotine vaping as a contributor to cancer in humans was retracted in 2023 because it too contained a multitude of inexcusable mistakes. The urge to attack vaping appears to be warping the ability of some scientists to fairly analyze their data.

 

Moreover, the retraction underscores the need for standardized protocols in vaping research. Studies examining the effects of vaping should reproduce the behavior of adult vapers as closely as possible in order to understand the impacts, positive or negative, on their health. 

Research like this retracted study, where mice were literally injected with tumor cells and exposed to nicotine, doesn’t tell us anything about the real-world risk of vaping. This echoes other debunked studies, such as those linking vaping to “popcorn lung” based on misidentified chemical exposures.

 

Conclusion: accountability a must

 

The broader implication of this retraction is a call for accountability in science. Anti-vaping research often amplifies risks while ignoring benefits, skewing public perception and policy. Vaping has helped millions reduce or quit smoking, yet flawed studies like this one threaten to undermine its role in tobacco harm reduction. 

By prioritizing ideological goals over empirical rigor, such research exemplifies bad science, wasting resources and eroding the public’s trust. The retraction of this study should serve as a wake-up call for the scientific community to demand higher standards and transparency in vaping research.

  • CannaAid and Peak: Something new for everyone.

Recent Articles

As a lifelong stoner, feminist, and teacher, Luna Stower does know how intersectional plant medicine can be.
“Whenever somebody sees ‘Sales Guru’ on my card, they ask how you become one,” he says. “I tell them that you spend your life in sales, and you go to Nepal to climb the Himalayas to meet the real gurus. You get the wisdom from them, then you bring it back down and apply it to your life.”
Cryptocurrency is taking the world by storm. It’s been over 15 years since the launch of Bitcoin, and although it’s more popular than ever before, it’s not the only form of crypto available today.
We know breaking up is hard to do, but sometimes the thrill is gone, and it’s time to move on. It doesn’t matter how long a brand’s been riding with you or how tight you are with the sales rep. If the product doesn’t perform, or worse, if the brand loses touch with the culture, it’s dead weight. And dead weight doesn’t just slow you down; it can drown you.
At HQ, we don’t shy away from controversy, but we also don’t exist to tear down legitimate players in the industry. We chose instead to invite both perspectives to weigh in.
Ali Bianco wants to elevate the cannabis world one pink pre-roll at a time. Since high school, she’s been sick of the stigma around weed and the idea that stoners are lazy and unkempt. Inspired by Blake Lively’s character smoking pink cigarettes in the 2011 film Hick, Ali decided to “make weed something beautiful” with a feminist kick.
In the early days, we bought flower based on two metrics: THC percentage and the vague promise of either indica or sativa. It was like ordering wine based on alcohol content and whether the label showed a beach or a mountain. We’ve come a long way.
I've witnessed firsthand how patient advocacy can profoundly change healthcare and people's lives. Today, I'm honored to lead ASA once again, as we intensify efforts to ensure medical cannabis reaches all patients who need it, fully integrated into our nation's healthcare system.